Zacks Investment Research downgraded shares of Blueprint Medicines (NASDAQ:BPMC) from a buy rating to a hold rating in a report issued on Thursday morning.

According to Zacks, “Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. “

Several other research analysts also recently commented on BPMC. Canaccord Genuity lifted their target price on shares of Blueprint Medicines from $56.00 to $66.00 and gave the stock a buy rating in a research note on Wednesday, September 20th. Goldman Sachs Group reaffirmed a buy rating and issued a $79.00 target price (up from $64.00) on shares of Blueprint Medicines in a research note on Wednesday, September 20th. BTIG Research started coverage on shares of Blueprint Medicines in a research note on Friday, September 29th. They issued a buy rating and a $90.00 target price on the stock. DA Davidson started coverage on shares of Blueprint Medicines in a research note on Friday, September 29th. They issued a buy rating and a $90.00 target price on the stock. Finally, Morgan Stanley lifted their target price on shares of Blueprint Medicines from $45.00 to $78.00 and gave the stock an overweight rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Blueprint Medicines has an average rating of Buy and a consensus price target of $84.10.

Shares of Blueprint Medicines (NASDAQ BPMC) traded up $0.79 during midday trading on Thursday, hitting $79.24. 158,100 shares of the company traded hands, compared to its average volume of 386,200. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a 12 month low of $31.35 and a 12 month high of $92.00. The stock has a market capitalization of $3,398.03, a P/E ratio of -23.24 and a beta of 1.29.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The firm had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. During the same period in the previous year, the firm earned ($0.62) earnings per share. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. equities analysts predict that Blueprint Medicines will post -3.75 EPS for the current year.

In other Blueprint Medicines news, insider Marion Dorsch sold 18,334 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the transaction, the insider now directly owns 18,334 shares of the company’s stock, valued at approximately $1,199,960.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey W. Albers sold 30,000 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $70.31, for a total transaction of $2,109,300.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,334 shares of company stock worth $3,978,160. Insiders own 3.40% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Rockefeller Financial Services Inc. purchased a new position in Blueprint Medicines during the 3rd quarter valued at $160,000. Ameritas Investment Partners Inc. increased its position in Blueprint Medicines by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,391 shares during the period. Fred Alger Management Inc. purchased a new position in Blueprint Medicines during the 2nd quarter valued at $203,000. SG Americas Securities LLC increased its position in Blueprint Medicines by 23.3% during the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 778 shares during the period. Finally, Turner Investments LLC purchased a new position in Blueprint Medicines during the 3rd quarter valued at $209,000. 83.54% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Blueprint Medicines (BPMC) Downgraded by Zacks Investment Research” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/15/blueprint-medicines-bpmc-downgraded-by-zacks-investment-research.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.